Evidence map›Paper›PMID 39369283›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease.

Michelle M Mielke, Matthew Anderson, J Wesson Ashford, Andreas Jeromin, Pei-Jung Lin, Allyson Rosen, Jamie Tyrone, Lawren VandeVrede, Deanna Willis, Oskar Hansson and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Patient views on blood-based biomarker tests for Alzheimer's disease in primary care.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Michelle M MielkeDepartment of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.ORCID 0000-0001-7177-1185
Matthew AndersonAtrium Health, Charlotte, North Carolina, USA.
J Wesson AshfordDepartment of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA.
Andreas JerominALZpath, Carlsbad, California, USA.
Pei-Jung LinCenter for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA.
Allyson RosenPalo Alto Veterans Affairs Medical Center, Palo Alto, California, USA.
Jamie TyronePatient Advocate, California, USA.
Lawren VandeVredeMemory and Aging Center, Department of Neurology, University of California, San Francisco, California, USA.
Deanna WillisDepartment of Family Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Ara S KhachaturianThe Campaign to Prevent Alzheimer's Disease, Rockville, Maryland, USA.
Suzanne E SchindlerDepartment of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.
Joan WeissUS Department of Health and Human Services, Health Resources and Services Administration, Bureau of Health Workforce, Rockville, Maryland, USA.
Richard BatrlaEisai Inc., Nutley, New Jersey, USA.
Sasha BozeatF. Hoffman-La Roche AG, Basel, Switzerland.
John R DwyerGlobal Alzheimer's Platform Foundation, Washington, District of Columbia, USA.
Drew HolzapfelThe Global CEO Initiative on Alzheimer's Disease, Philadelphia, Pennsylvania, USA.
Daryl Rhys JonesEisai Inc., Nutley, New Jersey, USA.
James F MurrayDavos Alzheimer's Collaborative, Philadelphia, Pennsylvania, USA.
Katherine A PartrickThe Global CEO Initiative on Alzheimer's Disease, Philadelphia, Pennsylvania, USA.
Emily SchollerThe Global CEO Initiative on Alzheimer's Disease, Philadelphia, Pennsylvania, USA.ORCID 0009-0000-5811-034X
George VradenburgThe Global CEO Initiative on Alzheimer's Disease, Philadelphia, Pennsylvania, USA.
Dylan YoungGuidehouse, McLean, Virginia, USA.
Joel B BraunsteinC2N Diagnostics, St. Louis, Missouri, USA.
Samantha C BurnhamEli Lilly & Co., Indianapolis, Indiana, USA.
Fabricio Ferreira de OliveiraFederal University of São Paulo, São Paulo, Brazil.
Yan Helen HuEisai Inc., Nutley, New Jersey, USA.
Soeren MattkeThe USC Brain Health Observatory, University of Southern California, Los Angeles, California, USA.
Zul MeraliBrain and Mind Institute, Aga Khan University, Nairobi, Kenya.
Mark MonaneC2N Diagnostics, St. Louis, Missouri, USA.
Marwan Noel SabbaghBarrow Neurological Institute, Phoenix, Arizona, USA.
Eli ShobinBiogen, Cambridge, Massachusetts, USA.
Michael W WeinerDepartments of Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology, University of California, San Francisco, California, USA.
Chinedu T Udeh-MomohDepartment of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

Funding

Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SHANNON L RISACHER · 2021 to 2026
$24.3M
Validation of Novel Plasma Biomarkers for Mixed Etiology DementiaK23AG073514 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI VANDEVREDE, LAWREN · 2021 to 2025
$1.0M
NIA NIH HHS K23 AG073514NIA NIH HHS P30 AG072947
6 · The paper itself

Abstract

Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood-based biomarkers (BBMs) for AD holds promise in enabling early detection of pathology and timely intervention. However, several critical considerations, such as the lack of consistent guidelines for assessing cognition, limited understanding of BBM test characteristics, insufficient evidence on BBM performance across diverse populations, and the ethical management of test results, must be addressed for widespread clinical implementation of BBMs in the United States. The Global CEO Initiative on Alzheimer's Disease BBM Workgroup convened to address these challenges and provide recommendations that underscore the importance of evidence-based guidelines, improved training for health-care professionals, patient empowerment through informed decision making, and the necessity of community-based studies to understand BBM performance in real-world populations. Multi-stakeholder engagement is essential to implement these recommendations and ensure credible guidance and education are accessible to all stakeholders.

Indexed as

Alzheimer DiseaseBiomarkersEarly DiagnosisHumansUnited StatesBiomarkersAlzheimer's diseaseamyloidbiomarkerblood‐based biomarkersclinical implementationclinical practicecognitive impairmentdisease‐modifying treatmentethicspatient journeyprimary caresecondary care

Identifiers

PMID39369283
PMCPMC11567842

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.